BrightPath Biotherapeutics Co., Ltd.

BrightPath will receive rights to Artisan Bio’s STAR-CRISPR editing platform. Credit: Herney Gómez from Pixabay. BrightPath Biotherapeutics and Artisan Bio have signed a research and licensing agreement to expedite the former’s allogeneic next-generation invariant natural killer T (iNKT) cell therapies to clinic. BrightPath will obtain non-exclusive rights to the STAR-CRISPR editing platform of Artisan Bio for accelerating the development of BrightPath’s iNKT cells. BrightPath Biotherapeutics CEO Kenichi Nagai stated: “This collaboration with Artisan provides us with the potential to create highly engineered allogeneic iNKT cellular therapy programmes for a range of indications, including solid tumours. “Artisan’s STAR-CRISPR system, and their leading editing efficiencies in iPSC cells, will enable our iNKT cell therapies to solve the persistence and efficacy problems faced by first-generation allogeneic CAR-T programmes.” Artisan will receive an upfront payment and research milestone payments, along with licence fees and development milestones from BrightPath. The company will also receive net sales milestones and royalties on future products. Artisan Bio CEO Ryan Gill stated: “We are excited for the BrightPath collaboration and the development of highly engineered iPS cells for cell therapy. “The BrightPath products will build upon our leading STAR-CRISPR platform, our highly optimised guides for allogeneic and proprietary target genes, and our rigorous off-target safety profiling.” Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Optimise your cell therapy process: a guide to cell thawing Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies. By Cytiva Thematic By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

BrightPath to receive non-exclusive rights to Artisan's STAR-CRISPR editing platform to accelerate development of BrightPath's invariant natural killer T (iNKT) cells Artisan to receive an upfront payment and research milestones, plus license fees, development milestones, net sales milestones, and royalty on future products TOKYO and DENVER, May 2, 2023 /PRNewswire/ -- BrightPath Biotherapeutics Co., Ltd. (TYO: 4594), a clinical stage biotechnology company focused on the development of cell therapies derived from invariant natural killer T (iNKT) cells, and Artisan Bio. Inc, a precision genome engineering and drug discovery company, today announced they have signed a research and licensing agreement to accelerate BrightPath's next-generation iNKT cell therapies to clinic. "This collaboration with Artisan provides BrightPath with the potential to create highly engineered allogeneic iNKT cellular therapy programs for a range of indications, including solid tumors," said Kenichi Nagai, BrightPath CEO. "Artisan's STAR-CRISPR system, and their leading editing efficiencies in iPSC cells, will enable BrightPath's iNKT cell therapies to solve the persistence and efficacy problems faced by first generation allogeneic CAR-T programs." "We are excited for the BrightPath collaboration and the development of highly engineered iPS cells for cell therapy," said Ryan Gill, Artisan Bio CEO. "The BrightPath products will build upon our leading STAR-CRISPR platform, our highly optimized guides for allogeneic and proprietary target genes, and our rigorous off-target safety profiling." Under this agreement, BrightPath will pay Artisan an upfront payment and research milestones for the development of CRISPR guides for the editing of BrightPath's iNKT cells. BrightPath has the right to a commercial license for the STAR-CRISPR guides and nuclease for a license fee plus development milestones, sales milestones, and a royalty on future products. About BrightPath: BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immuno-therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies currently in clinical trials, immunomodulatory antibodies and new drugs targeted at cancer specific neoantigens. For more information, visit . About Artisan: Artisan Bio is a world-leader in CRISPR genome engineering technology and provides drug developers with advanced genome engineering and drug discovery tools for the research and commercialization of cell and gene therapies, including companies such as Takeda and Cabaletta Bio. Artisan's proprietary STAR-CRISPR gene editing platform delivers leading editing efficiencies in multiple cell types including iPSC and T-cells, and is available through non-exclusive licenses. Artisan's SyionAI platform utilizes high-throughput CRISPR editing for novel drug discovery. For more information, visit . SOURCE Artisan Bio

DUBLIN, Dec. 13, 2022 /PRNewswire/ -- The "House Dust Mite Allergy Treatment Market By Treatment, By Type, By Route of administration, By Distribution channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering. The global house dust mite allergy treatment market was valued at $1,481.2 million in 2021, and is projected to reach $5,189.3 million by 2031, registering a CAGR of 13.4% from 2022 to 2031. The growth of the global house dust mite allergy treatment market is driven by increasing in-house allergens, rise in awareness among the population about allergic reactions caused due to various types of allergens, and alarming surge in prevalence of allergy diseases. According to the Allergy and Asthma Foundation, in March 2020, it was observed that dust mites are the leading causes of in-house allergies. Furthermore, according to the World Health Organization (WHO), in 2020, it was reported that around 70% of allergic reactions are caused due to house dust mite allergen. In addition, chronic exposure to house dust mites impacts the health of population with asthma, and those who are sensitive and allergic to mites. Thus, the population diagnosed with allergic rhinitis and asthma are more prone to house dust mite allergy. According to the Center for Disease Control and Prevention (CDC), in 2020, it was reported that around 25.2 million population is diagnosed from asthma, globally. According to the Thermo Fisher Scientific, it was reported that around 90% of population diagnosed with allergic asthma are sensitized to house dust mite allergens. Moreover, according to the Center for Disease Control and Prevention, in 2020, it was reported that around 60 million population were diagnosed with allergic rhinitis in the U.S. Thus, increase in prevalence of asthma and rhinitis fuels the growth of the house dust mite allergy treatment market. However, rise in hygiene practices reduces the occurrence of house dust mite allergy, which hampers the growth of the house dust mite treatment market. Furthermore, lack of proper diagnosis of allergy symptoms caused by house dust mites acts as a key deterrent factor for the global market. On the contrary, increase in awareness among population about various treatments available for allergy diseases is expected to open new avenues for the expansion of the market. This has further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the market growth. The global house dust mite treatment market is segmented into treatment, type, route of administration, distribution channel, and region. On the basis of treatment, the market is categorized into antihistamine, immunotherapy, and others. By type, it is bifurcated into prescription and over-the-counter. Depending on route of administration, it is segregated into oral medication and nasal administration. As per distribution channel, it is differentiated into hospital pharmacy, online pharmacy, and retail pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Key Market Segments By Treatment Antihistamine Immunotherapy Other By Type Prescription based drugs Over the counter drugs By Route of administration Oral medication Nasal administration By Distribution channel Hospital Pharmacy Online Pharmacy Retail Pharmacy By Region North America U.S. Canada Mexico Europe Germany France U.K. Italy Spain Rest of Europe Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific LAMEA Brazil Saudi Arabia South Africa Rest of LAMEA Key Market Players ALK Abello A S Allergy Therapeutics PLC Bayer AG Catalent Pharma Solutions Limited GlaxoSmithKline plc. Johnson and Johnson Merz Pharma GmbH an Co. KGaA Sanofi Seqirus UK Limited Shionogi and Co. Ltd. Key Findings of the Study By treatment, the others segment was the highest contributor to the market in 2021. On the basis of type, prescription-based drugs segment dominated the market in 2021. Depending on route of administration, the oral medication segment exhibited the highest growth in 2021, and is expected to continue this trend during the forecast period. As per distribution channel, hospital pharmacy was the prominent segment in 2021. Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. Key Topics Covered: CHAPTER 1: INTRODUCTION CHAPTER 2: EXECUTIVE SUMMARY CHAPTER 3: MARKET OVERVIEW CHAPTER 4: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT CHAPTER 5: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE CHAPTER 6: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION CHAPTER 7: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL CHAPTER 8: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY REGION CHAPTER 9: COMPANY LANDSCAPE CHAPTER 10: COMPANY PROFILES For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets